New hope for tough leukemia? early trial tests AB8939
NCT ID NCT05211570
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called AB8939, given daily through a vein, for people with acute myeloid leukemia that has come back or not responded to standard treatments. About 78 participants will receive AB8939, sometimes with another drug called venetoclax. The main goals are to find a safe dose and see if the drug can shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AB8939 (a drug given intravenously) and venetoclax (a chemotherapy pill)
What this could lead to
If successful, this could point toward a new treatment option for people with acute myeloid leukemia that has come back or not responded to other therapies.
What could go wrong
This is an early phase 1/2 trial with only 78 participants, so it is too soon to know if AB8939 is safe or effective. The drug may cause serious side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clínica Universidad de Navarra
RECRUITINGPamplona, Spain
-
General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante)
RECRUITINGAlicante, Spain
-
Hospital San Pedro de Alcantara
RECRUITINGCáceres, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, Spain
-
Hospital Universitario Quirónsalud
RECRUITINGMadrid, Spain
-
Institut Paoli Calmettes
NOT_YET_RECRUITINGMarseille, France
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
MD Anderson Cancer Center Madrid
RECRUITINGMadrid, Spain
-
National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit
RECRUITINGAthens, Greece
-
Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío)
RECRUITINGSeville, Spain